Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CN9Q
|
|||
| Former ID |
DCL000345
|
|||
| Drug Name |
CP-724714
|
|||
| Synonyms |
CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 2 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H27N5O3
|
|||
| Canonical SMILES |
CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)C=CCNC(=O)COC)C
|
|||
| InChI |
1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+
|
|||
| InChIKey |
LLVZBTWPGQVVLW-SNAWJCMRSA-N
|
|||
| CAS Number |
CAS 845680-17-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14907431, 24164339, 45621889, 50100096, 74684963, 99436923, 103641275, 109693627, 118049527, 123051111, 124757046, 125163850, 126726428, 131480713, 135263665, 135653490, 136340153, 136367341, 136367983, 136920311, 142560911, 144115847, 144236584, 152258589, 162011933, 162037476, 162202660, 163642442, 163686131, 164825263, 172086266, 174561044, 177749068, 180371631, 185998810, 188899554, 198937309, 202547998, 223366212, 223669186, 223705210, 223936181, 226472380, 230530185, 251971144, 252160232, 252215195, 252219937, 252471201, 252543303
|
|||
| ChEBI ID |
CHEBI:91331
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7883). | |||
| REF 2 | ClinicalTrials.gov (NCT00102895) A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer. U.S. National Institutes of Health. | |||
| REF 3 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.